Author response for 'Findings for <scp>iGlarLixi</scp> vs <scp>BIAsp</scp> 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics'

Authors :: null Philip D. Home
null Rory J. McCrimmon
null Julio Rosenstock
null Matthias Blüher
null Katrin Pegelow
null Lydie Melas‐Melt
null Khier Djaballah
null Francesco Giorgino
null the SoliMix trial investigators
Publication Year :: 2022
Publisher :: Wiley, 2022.

Full Text Access

Tools